Twist Bioscience Corp

Public Equity (NASDAQ)PublicBiotechSynthetic Biology

📍 South San Francisco, CA, United States• Founded 2013• 979 employees

StreetZero Signal 58

Be the first to signal interest

About Twist Bioscience Corp

Twist Bioscience Corporation (Nasdaq: TWST) is a synthetic biology company that has developed a silicon-based DNA synthesis platform to industrialize the engineering of biology. The company provides high-quality synthetic DNA to customers and is described as a mid-cap growth and value biotech firm. It is headquartered in South San Francisco, CA and went public with prior total funding of $321M across 11 rounds since 2014.

LATEST FUNDINGRule 144

$385K

Announced 2026-10-09

TOTAL RAISED$321M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Twist Bioscience Corp.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES979

FOUNDED2013

HQSouth San Francisco, CA, United States

Industry

Public Equity (NASDAQ)

Investors

Foresight Capital Fidelity Investments

Key highlights

Completed $323.7M follow-on public offering of 3.2M shares at $110 per share.
Raised total of $321M across 11 rounds prior to public status with 41 investors.
Operates silicon platform for high-quality synthetic DNA production.
Public company with 979 employees and market cap over $12B.

Ask StreetZero about Twist Bioscience Corp

Put our AI to work on this deal.

What is Twist Bioscience Corp's value proposition?Who are Twist Bioscience Corp's competitors?Why does this raise matter?Summarize Twist Bioscience Corp for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Affirm Holdings, Inc.

$5.1M

ZSCALER, INC.

$5.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.